2024 Amyloidosis Forum Annual Meeting

Isabelle Lousada has been the driving force behind ARC, building successful collaborations and programs across the sectors to advance the science and understanding of the amyloidosis diseases.

Isabelle was diagnosed with AL amyloidosis and was one of the first patients to successfully undergo a stem cell transplant. For the past twenty years she has been committed to empowering other patients while serving on several boards and committees, speaking at leadership meetings and key events to encourage research, increase access, and support the critical and unmet needs of amyloidosis patients.

Angela Dispenzieri, M.D., is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic. She has joint appointments in the Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, and the Department of Molecular Medicine. Dr. Dispenzieri holds the academic rank of Professor of Medicine and of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, and she is recognized with the distinction of a named professorship, the Serene M. and Frances C. Durling Professorship. She joined the staff of Mayo Clinic in 1998 and served as Chair of Hematology Research from 2014 to 2022. She served as the President of the International Society of Amyloidosis from 2016 to 2018, and currently chairs the Mayo Clinic Amyloid Interest Group.

Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus.

He has published over 350 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults.